ライフサイエンスコーパス: nasopharyngeal carcinoma

1 ry leukoplakia) or latent infection (such as nasopharyngeal carcinoma).

2 rr virus (EBV) causes Burkitt's lymphoma and nasopharyngeal carcinoma.

3 a variety of ailments, from benign rashes to nasopharyngeal carcinoma.

4 580V, is associated with IgA nephropathy and nasopharyngeal carcinoma.

5 transplant lymphoproliferative disorder, and nasopharyngeal carcinoma.

6 event or enhance treatment of EBV-associated nasopharyngeal carcinoma.

7 nd represent a promising future direction in nasopharyngeal carcinoma.

8 < .001) of this finding in the patients with nasopharyngeal carcinoma.

9 hought to be important to the development of nasopharyngeal carcinoma.

10 ality in 36% (11 of 31) of the patients with nasopharyngeal carcinoma.

11 is not found in EBV strains associated with nasopharyngeal carcinoma.

12 velopment of several malignancies, including nasopharyngeal carcinoma.

13 is the standard of care for locally advanced nasopharyngeal carcinoma.

14 ted with a variety of malignancies including nasopharyngeal carcinoma.

15 as the standard of care in locally advanced nasopharyngeal carcinoma.

16 ral forms of cancer, including lymphomas and nasopharyngeal carcinoma.

17 states exemplified by Burkitt's lymphoma and nasopharyngeal carcinoma.

18 sociated tumors such as Burkitt lymphoma and nasopharyngeal carcinoma.

19 ents with hemophilia, autoimmune disease, or nasopharyngeal carcinoma.

20 epistaxis for 2 years and was diagnosed with nasopharyngeal carcinoma.

21 th predisposition to autoimmune diseases and nasopharyngeal carcinoma.

22 ese cell types, such as Burkitt lymphoma and nasopharyngeal carcinoma.

23 all survival over chemoradiotherapy alone in nasopharyngeal carcinoma.

24 ty profile in patients with stage T(any)N3M0 nasopharyngeal carcinoma.

25 t line treatment for recurrent or metastatic nasopharyngeal carcinoma.

26 manageable toxicities in platinum-resistant nasopharyngeal carcinoma.

27 rate biomarker for the routine management of nasopharyngeal carcinoma.

28 arget volume delineation for radiotherapy in nasopharyngeal carcinoma.

29 atlas for neck target volume delineation in nasopharyngeal carcinoma.

30 cies Hodgkin and Burkitt lymphoma as well as nasopharyngeal carcinoma.

31 val in patients with locoregionally advanced nasopharyngeal carcinoma.

32 as an aetiological factor in B lymphomas and nasopharyngeal carcinoma.

33 oth lymphoid and epithelial cells, including nasopharyngeal carcinoma.

34 e development of multiple cancers, including nasopharyngeal carcinoma.

35 showed that it improves overall survival in nasopharyngeal carcinoma.

36 as Burkitt and Hodgkin lymphoma, as well as nasopharyngeal carcinoma.

37 also causes nonlymphoid malignancies such as nasopharyngeal carcinoma.

38 hogen associated with Burkitt's lymphoma and nasopharyngeal carcinoma.

39 with the development of B cell lymphomas and nasopharyngeal carcinomas.

40 viral reactivation occurs in EBV-associated nasopharyngeal carcinomas.

41 1.23-2.54), liver cancer (1.70, 1.10-2.63), nasopharyngeal carcinoma (26.05, 11.77-57.65), and lymph

42 cell lines from patients with EBV-associated nasopharyngeal carcinoma (3 out of 22, P = 0.0003), wher

43 (EBV), which is the causative agent of most nasopharyngeal carcinoma, also employs several immunosup

44 ated recent trends in the incidence rates of nasopharyngeal carcinoma among Chinese living in Los Ang

45 olleagues report these results for recurrent nasopharyngeal carcinoma, an aggressive malignancy assoc

46 Notable exceptions were observed for nasopharyngeal carcinoma, an EBV-associated cancer, and

47 LMP2 transcripts are detected in nasopharyngeal carcinoma, an epithelial-cell malignancy.

48 expressed in the EBV-associated malignancies nasopharyngeal carcinoma and Burkitt's lymphoma, and are

49 ted with several types of cancers, including nasopharyngeal carcinoma and Burkitt's lymphoma.

50 e protein 1 (LMP1) gene has been reported in nasopharyngeal carcinoma and EBV-associated malignant ly

51 n the EBV-associated epithelial malignancies nasopharyngeal carcinoma and gastric carcinoma, and thes

52 d association with the epithelial malignancy nasopharyngeal carcinoma and has also been reported in o

53 ithin the terminal repeats is active in both nasopharyngeal carcinoma and Hodgkin's disease tissues.

54 pattern is typical of EBV gene expression in nasopharyngeal carcinoma and Hodgkin's disease, and diff

55 essed in primary biopsies from patients with nasopharyngeal carcinoma and Hodgkin's disease, where LM

56 munotherapeutic strategies to tumors such as nasopharyngeal carcinoma and Hodgkin's lymphoma that hav

57 L1-TR, active in nasopharyngeal carcinoma and Hodgkin's lymphoma, is loca

58 ears; age range, 27-68 years) with untreated nasopharyngeal carcinoma and in 31 control subjects (17

59 pAIR correctly identifies every patient with nasopharyngeal carcinoma and inflammatory bowel disease

60 EBV) LMP1 protein is frequently expressed in nasopharyngeal carcinoma and is essential for the transf

61 nvolved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI

62 ially has classified formaldehyde as causing nasopharyngeal carcinoma and myeloid leukemia.

63 chemotherapy in patients with non-metastatic nasopharyngeal carcinoma and obtained updated data for p

64 y in certain epithelial pathologies, such as nasopharyngeal carcinoma and oral hairy leukoplakia, ind

65 in-Barr virus (EBV)-associated malignancies, nasopharyngeal carcinoma and posttransplant lymphoma, ra

66 iously reported isolates from EBV-associated nasopharyngeal carcinomas and Burkitt's lymphomas occurr

67 produced complete remissions of EBV-positive nasopharyngeal carcinomas and lymphomas developing in im

68 posttransplant lymphomas, Hodgkin's disease, nasopharyngeal carcinoma, and AIDS-related lymphomas.

69 ion of tumors - including related lymphomas, nasopharyngeal carcinoma, and gastric adenocarcinoma - i

70 several malignancies as Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's disease.

71 ncer tissues, such as large B cell lymphoma, nasopharyngeal carcinoma, and melanoma.

72 nt in Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and nasal lymphoma.

73 pment of Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and other EBV-associated disea

74 onsistently been associated with the risk of nasopharyngeal carcinoma, and patients with Hodgkin lymp

75 rasts with EBV-associated Hodgkin's disease, nasopharyngeal carcinoma, and post-transplant lymphoprol

76 ncer death due to liver cancer, lung cancer, nasopharyngeal carcinoma, and stomach cancer.

77 ithelial cells derived from gastric cancers, nasopharyngeal carcinomas, and normal oral keratinocytes

78 s endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cau

79 hlights recent advances in the management of nasopharyngeal carcinoma as a result of these endeavors.

80 ssociated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies

81 In nasopharyngeal carcinoma-associated cell type, we identi

82 of an EBV-based screening strategy to detect nasopharyngeal carcinoma at early stages and hopefully r

83 primary EBV-positive Hodgkin's lymphoma and nasopharyngeal carcinoma biopsies correlates with the nu

84 a herpesvirus linked to malignancies such as nasopharyngeal carcinoma, Burkitt's lymphoma, and Hodgki

85 man herpesvirus, is latently present in most nasopharyngeal carcinomas, Burkitt lymphomas, and some g

86 (37 of 62 subjects) among the patients with nasopharyngeal carcinoma but only 3% (two of 62 subjects

87 This resembles the N classification of nasopharyngeal carcinoma but without a lower neck lymph

88 therapy in the treatment of locally advanced nasopharyngeal carcinoma, but its reproducibility was un

89 ove the outcomes for locoregionally advanced nasopharyngeal carcinoma by testing the feasibility and

90 he cell cycle, was consistently expressed in nasopharyngeal carcinomas by immunohistochemical analysi

91 iR-BART6 found in Daudi Burkitt lymphoma and nasopharyngeal carcinoma C666-1 cell lines suppressed pr

92 on in epithelial cells (including the C666-1 nasopharyngeal carcinoma cell line), although Na does no

93 ellular carcinoma cell line, and KB, a human nasopharyngeal carcinoma cell line.

94 originally reported but also in a number of nasopharyngeal carcinoma cell lines and a gastric carcin

95 Nasopharyngeal carcinoma cell lines constitutively expre

96 lytic viral gene expression in EBV-positive nasopharyngeal carcinoma cells and lymphoblastoid cells,

97 llular accumulation of HIF-1alpha of hypoxic nasopharyngeal carcinoma cells and mediates the radiatio

98 Exosomes produced by EBV-infected nasopharyngeal carcinoma cells contain high levels of th

99 s type I interferon production, and in human nasopharyngeal carcinoma cells results in almost complet

100 ter in CTAR1-expressing epithelial cells and nasopharyngeal carcinoma cells.

101 has been shown to mediate chemomigration in nasopharyngeal carcinoma cells.

102 s the radiation-resistant phenotype of these nasopharyngeal carcinoma cells.

103 4 X 10(6) folate-receptor-positive KB (human nasopharyngeal carcinoma) cells into athymic mice yielde

104 izing action on KBvin (vincristine-resistant nasopharyngeal carcinoma) cells, a multidrug resistant c

105 + cells from the two donor groups, KB (human nasopharyngeal carcinoma) cells, and M07e (human megakar

106 8 x 10(6) folate receptor-positive KB (human nasopharyngeal carcinoma) cells, yielding 0.2- to 0.6-g

107 ts, and arrested cells at the G0/G1 phase in nasopharyngeal carcinoma CNE-2Z cells.

108 We further demonstrate in nasopharyngeal carcinoma CNE2 and 5-8F cells that this c

109 ts in the hypoxic regions of tumor formed by nasopharyngeal carcinoma CNE2 cells and breast cancer MD

110 ing Epstein-Barr virus serologic testing for nasopharyngeal carcinoma delivered every 1 to 4 years wa

111 er B-cell lymphoma-, gastric carcinoma-, and nasopharyngeal carcinoma-derived cell lines.

112 e guidelines are in keeping with advances in nasopharyngeal carcinoma diagnosis and treatment, embody

113 uidelines incorporate the latest advances in nasopharyngeal carcinoma diagnosis and treatment.

114 al carcinoma patients and 5860 controls from nasopharyngeal carcinoma endemic areas identifies a tota

115 at are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), thi

116 ients older than 18 years with stage IIB-IVB nasopharyngeal carcinoma from 19 centres in North Americ

117 ogies ranging from oral hairy leukoplakia to nasopharyngeal carcinoma, from infectious mononucleosis

118 d with several human malignancies, including nasopharyngeal carcinoma, gastric cancer, and lymphoma.

119 he development of various cancers, including nasopharyngeal carcinoma, gastric cancer, Burkitt lympho

120 to this systematic review and meta-analysis, nasopharyngeal carcinoma has a significantly higher ADC

121 The treatment of childhood nasopharyngeal carcinoma has been adapted from adult reg

122 Patients with N3 nasopharyngeal carcinoma have a high risk of distant met

123 previously in EBV-associated tumors such as nasopharyngeal carcinoma, Hodgkin's disease (HD), and T/

124 , lung cancer (HR, 3.49; 95% CI, 2.08-5.88), nasopharyngeal carcinoma (HR, 2.79; 95% CI, 1.27-6.12),

125 of endemicity.Keywords: Epstein-Barr virus, nasopharyngeal carcinoma, humoral immune response, antib

126 may have implications for the development of nasopharyngeal carcinoma in high-risk populations in whi

127 From 1992 to 2002, the rates of nasopharyngeal carcinoma in these two populations decrea

128 However, since the 1980s, nasopharyngeal carcinoma incidence has fallen among both

129 Sixteen patients with nasopharyngeal carcinoma initially treated with 50.0-88.

130 Nasopharyngeal carcinoma is a major cancer that develops

131 Nasopharyngeal carcinoma is a malignancy that is prevale

132 Nasopharyngeal carcinoma is a rarely seen tumor in child

133 Nasopharyngeal carcinoma is an aggressive malignancy ori

134 Nasopharyngeal carcinoma is characterised by distinct ge

135 d chemoradiation treatment for patients with nasopharyngeal carcinoma is feasible, and might delay th

136 Nasopharyngeal carcinoma is much more common in Asian co

137 , and face-to-face consultations in managing nasopharyngeal carcinoma is urgently needed amid the cur

138 V) is invariably present in undifferentiated nasopharyngeal carcinomas, is found sporadically in othe

139 Nasopharyngeal carcinoma, Kaposi's sarcoma, and B-cell l

140 analysis of global gene expression in human nasopharyngeal carcinoma KB cells grown in folate-deplet

141 of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an est

142 ked to the development of cancers, including nasopharyngeal carcinoma, lymphomas, and gastric cancer.

143 man malignancies including Burkitt lymphoma, nasopharyngeal carcinoma, lymphoproliferative disease an

144 related central nervous system lymphomas and nasopharyngeal carcinomas) may allow novel, EBV-based ta

145 in about half of the patients with untreated nasopharyngeal carcinoma, may reflect tumor proximity to

146 ein 1 (LMP1), is detected in at least 70% of nasopharyngeal carcinoma (NPC) and all EBV-infected prei

147 can cause various human malignancies such as nasopharyngeal carcinoma (NPC) and gastric cancer (GC).

148 U, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due

149 urrently involved in structural variation in nasopharyngeal carcinoma (NPC) and the identification of

150 Incidence rates of nasopharyngeal carcinoma (NPC) are much higher among Chi

151 ions to tumorigenesis and chemoresistance in nasopharyngeal carcinoma (NPC) are not evident.

152 Patients with nonmetastatic nasopharyngeal carcinoma (NPC) are primarily treated by

153 stablished epithelial cell lines and primary nasopharyngeal carcinoma (NPC) biopsy specimens.

154 Nasopharyngeal carcinoma (NPC) cell lines are important

155 In this study, using nasopharyngeal carcinoma (NPC) cells as a model system,

156 g Burkitt's lymphoma Rael cells and cultured nasopharyngeal carcinoma (NPC) cells contained nuclear S

157 In this study, exosomes released from nasopharyngeal carcinoma (NPC) cells harboring latent EB

158 It ranges from lower expression in nasopharyngeal carcinoma (NPC) cells to higher expressio

159 ypes, including Burkitt lymphoma (BL) cells, nasopharyngeal carcinoma (NPC) cells, and lymphoblastoid

160 are constitutively activated and nuclear in nasopharyngeal carcinoma (NPC) cells.

161 llular adhesion molecule-1 (ICAM-1) in human nasopharyngeal carcinoma (NPC) cells.

162 Nasopharyngeal carcinoma (NPC) demonstrates significant

163 tion and acquired genetic alterations during nasopharyngeal carcinoma (NPC) development remains vague

164 m to assess its ability of real-time in vivo nasopharyngeal carcinoma (NPC) diagnosis and post-treatm

165 Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) exhibits unusual geograph

166 ted tumors such as Hodgkin lymphoma (HL) and nasopharyngeal carcinoma (NPC) express FasL, we determin

167 Conventional treatment for nasopharyngeal carcinoma (NPC) frequently fails and is a

168 Undifferentiated nasopharyngeal carcinoma (NPC) has a 100% association wi

169 al T lymphocyte infiltrate found in cases of nasopharyngeal carcinoma (NPC) has been implicated in th

170 Nasopharyngeal carcinoma (NPC) has extremely skewed ethn

171 er, the role of Met/HGF signaling pathway in nasopharyngeal carcinoma (NPC) has not been evaluated.

172 the correlation between APLNR expression and nasopharyngeal carcinoma (NPC) has not been reported.

173 Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvig

174 Nonkeratinizing nasopharyngeal carcinoma (NPC) is 100% associated with E

175 Nasopharyngeal carcinoma (NPC) is a highly metastatic ca

176 The epithelial-derived nasopharyngeal carcinoma (NPC) is a rare tumor in most o

177 Nasopharyngeal carcinoma (NPC) is a unique epithelial ma

178 Nasopharyngeal carcinoma (NPC) is an aggressive head and

179 Nasopharyngeal carcinoma (NPC) is an EBV-associated epit

180 Nasopharyngeal carcinoma (NPC) is an endemic cancer in s

181 Undifferentiated nasopharyngeal carcinoma (NPC) is an epithelial malignan

182 Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus

183 Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-

184 Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-

185 Nasopharyngeal carcinoma (NPC) is an invasive cancer wit

186 Nasopharyngeal carcinoma (NPC) is associated with EBV in

187 Radioresistance of EBV-associated nasopharyngeal carcinoma (NPC) is associated with poor p

188 Nasopharyngeal carcinoma (NPC) is characteristic for its

189 Nasopharyngeal carcinoma (NPC) is closely associated wit

190 Nasopharyngeal carcinoma (NPC) is endemic in China and S

191 reatment of EBV-associated cancer.IMPORTANCE Nasopharyngeal carcinoma (NPC) is highly associated with

192 late-stage Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) is incurable, and its tre

193 Undifferentiated nasopharyngeal carcinoma (NPC) is latently infected with

194 Recurrent nasopharyngeal carcinoma (NPC) is the main cause of poor

195 Nasopharyngeal carcinoma (NPC) is the most frequent Epst

196 Nasopharyngeal carcinoma (NPC) is universally associated

197 l OPC regional lymph node (N) categories and nasopharyngeal carcinoma (NPC) N categories.

198 ostic tools for monitoring disease status in nasopharyngeal carcinoma (NPC) patients.

199 enhancing in vivo detection and diagnosis of nasopharyngeal carcinoma (NPC) patients.

200 treatment is a robust prognostic marker for nasopharyngeal carcinoma (NPC) patients.

201 Nasopharyngeal carcinoma (NPC) presents unique challenge

202 d with acute side effects of radiotherapy in nasopharyngeal carcinoma (NPC) remain largely unknown.

203 Given salvage treatment for recurrent nasopharyngeal carcinoma (NPC) remains a clinical dilemm

204 However, its role in nasopharyngeal carcinoma (NPC) remains unexplored.

205 Nasopharyngeal carcinoma (NPC) results from the aberrant

206 de polymorphisms (SNPs) in PIN1 promoter and nasopharyngeal carcinoma (NPC) risk with a small sample

207 frequently present in Chinese and Indonesian nasopharyngeal carcinoma (NPC) samples.

208 fragment have been previously identified in nasopharyngeal carcinoma (NPC) tissues.

209 the expression of MMP-2, MMP-9, and VEGF in nasopharyngeal carcinoma (NPC) tumors by using three NPC

210 mprehensive profile of EBV miRNAs in primary nasopharyngeal carcinoma (NPC) tumors including estimate

211 sine (cidofovir) on the EBV-associated tumor nasopharyngeal carcinoma (NPC) was evaluated in NPC xeno

212 d brain injury (RBI) model and patients with nasopharyngeal carcinoma (NPC) who received radiation th

213 eatment of Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) with EBV-specific cytotox

214 Genetic susceptibility is likely involved in nasopharyngeal carcinoma (NPC), a cancer caused by Epste

215 also elevated in the LMP1-expressing tumor, nasopharyngeal carcinoma (NPC), a highly invasive neopla

216 Epstein-Barr virus (EBV) causes most nasopharyngeal carcinoma (NPC), a malignancy endemic in

217 n EBV-transformed lymphoblastoid cell lines, nasopharyngeal carcinoma (NPC), a subset of Hodgkin's di

218 Nasopharyngeal carcinoma (NPC), an EBV-associated malign

219 ansplant lymphoproliferative disease (PTLD), nasopharyngeal carcinoma (NPC), and AIDS-associated lymp

220 B cell lymphomas, Hodgkin's disease (HD) and nasopharyngeal carcinoma (NPC), and by its unique abilit

221 's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma (NPC), and lymphomas that devel

222 g tumors that have latent infection, such as nasopharyngeal carcinoma (NPC), and oral hairy leukoplak

223 BV is associated with the epithelial cancer, nasopharyngeal carcinoma (NPC), and the lymphoid maligna

224 survival rates in cancer patients, including nasopharyngeal carcinoma (NPC), breast cancer and hepato

225 tumor burden and prognosis in patients with nasopharyngeal carcinoma (NPC), but data on the relation

226 cellular differentiation is a key feature of nasopharyngeal carcinoma (NPC), but it also presents as

227 BACKGROUNDEBV is associated with nasopharyngeal carcinoma (NPC), but the existence of a N

228 identified multiple susceptibility loci for nasopharyngeal carcinoma (NPC), but the underlying biolo

229 nant diseases, including Burkitt's lymphoma, nasopharyngeal carcinoma (NPC), certain types of lymphom

230 ly linked with human B-cell malignancies and nasopharyngeal carcinoma (NPC), establishes three types

231 related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC),

232 associated with many human cancers, such as nasopharyngeal carcinoma (NPC), Hodgkin's disease, and g

233 n-Barr virus (EBV), aetiologically linked to nasopharyngeal carcinoma (NPC), is the first human virus

234 sive-stage small cell lung cancer (ES-SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung canc

235 the one viral protein uniformly expressed in nasopharyngeal carcinoma (NPC), represents a prime targe

236 In cases of nasopharyngeal carcinoma (NPC), the auditory apparatus i

237 In the EBV-associated epithelial tumor nasopharyngeal carcinoma (NPC), the virus-encoded latent

238 ide association study (GWAS) derived PRS for nasopharyngeal carcinoma (NPC), using a multi-center stu

239 Nasopharyngeal carcinoma (NPC), which is closely associa

240 uding Burkitt lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (NPC).

241 s (EBV) have been proposed for screening for nasopharyngeal carcinoma (NPC).

242 both lymphoid and epithelial cells including nasopharyngeal carcinoma (NPC).

243 in-Barr virus and is frequently expressed in nasopharyngeal carcinoma (NPC).

244 perties in EBV-associated cancers, including nasopharyngeal carcinoma (NPC).

245 disease, and Burkitt's lymphoma, as well as nasopharyngeal carcinoma (NPC).

246 nancies, including the epithelial malignancy nasopharyngeal carcinoma (NPC).

247 lymphoid and epithelial malignancies such as nasopharyngeal carcinoma (NPC).

248 associated with multiple cancers, including nasopharyngeal carcinoma (NPC).

249 expressed in the EBV associated malignancy, nasopharyngeal carcinoma (NPC).

250 rent AJCC/UICC TNM 8(th) edition for staging nasopharyngeal carcinoma (NPC).

251 tors improve outcomes in relapsed/metastatic nasopharyngeal carcinoma (NPC).

252 s have not been sufficiently investigated in nasopharyngeal carcinoma (NPC).

253 e rarely been investigated in the context of nasopharyngeal carcinoma (NPC).

254 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC).

255 oup of patients with locoregionally advanced nasopharyngeal carcinoma (NPC).

256 velopment of CD44(+/High) stem-like cells in nasopharyngeal carcinoma (NPC).

257 in-Barr virus (EBV) to the aggressiveness of nasopharyngeal carcinoma (NPC).

258 ethylation are hallmarks of undifferentiated nasopharyngeal carcinoma (NPC).

259 an oncogene in epithelial carcinomas such as nasopharyngeal carcinoma (NPC).

260 ssion of the highly invasive EBV malignancy, nasopharyngeal carcinoma (NPC).

261 target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC).

262 ssociated with epithelial cancers, including nasopharyngeal carcinoma (NPC).

263 Radiotherapy is the standard therapy for nasopharyngeal carcinoma (NPC); however, radioresistance

264 es, including virtually all undifferentiated nasopharyngeal carcinomas (NPC) and a portion of gastric

265 Nonkeratinizing nasopharyngeal carcinomas (NPC) are >95% associated with

266 Nasopharyngeal carcinomas (NPC) are malignancies that ha

267 sion between 31 laser-capture-microdissected nasopharyngeal carcinomas (NPCs) and 10 normal healthy n

268 Undifferentiated nasopharyngeal carcinomas (NPCs) are commonly present wi

269 n abundance between blood and throat washes, nasopharyngeal carcinomas (NPCs) from areas of endemicit

270 us (EBV) infection promotes undifferentiated nasopharyngeal carcinomas (NPCs) in humans, but the mech

271 to explore infectious agents associated with nasopharyngeal carcinomas (NPCs), we employed our high-t

272 for an increased hazard of myeloid leukemia, nasopharyngeal carcinoma, or other upper airway tumors f

273 e effective in the treatment of EBV-positive nasopharyngeal carcinomas passaged in nude mice than eit

274 therefore subjected to negative selection in nasopharyngeal carcinoma pathogenesis.

275 A meta-GWAS including 5073 nasopharyngeal carcinoma patients and 5860 controls from

276 ponses were rescued in approximately half of nasopharyngeal carcinoma patients by peptide and cytokin

277 our virus, is detectable in more than 90% of nasopharyngeal carcinoma patients in endemic regions.

278 MATERIAL/METHODS: The study included 10 nasopharyngeal carcinoma patients under the age of 18 ye

279 or antigen has been significantly altered in nasopharyngeal carcinoma patients.

280 has been found in infectious mononucleosis, nasopharyngeal carcinoma, posttransplant lymphoma, and n

281 II trial of locally recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients, first-line

282 plication of BRISK to archival tissue from a nasopharyngeal carcinoma resulted in identification of E

283 of whole-genome sequencing of EBV-associated nasopharyngeal carcinomas revealed that structural varia

284 stemic treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

285 international multidisciplinary panel of 50 nasopharyngeal carcinoma specialists from 17 countries a

286 Many nasopharyngeal carcinoma susceptibility loci have been i

287 parts of its sequences have been reported as nasopharyngeal carcinoma susceptibility protein and medu

288 with single-cell and bulk profiles, we find nasopharyngeal carcinoma susceptibility robustly associa

289 chemotherapy in patients with non-metastatic nasopharyngeal carcinoma that completed accrual before D

290 ologically confirmed recurrent or metastatic nasopharyngeal carcinoma that had progressed after at le

291 People with recurrent or metastatic nasopharyngeal carcinoma that progressed after chemother

292 , solid tumors such as renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, meduloblasto

293 Immunohistochemical analyses of nasopharyngeal carcinoma tumors revealed that STAT3, STA

294 enically conserved among virus isolates from nasopharyngeal carcinoma tumors.

295 cal trial, 49 patients with stage T(any)N3M0 nasopharyngeal carcinoma were enrolled and received the

296 In the current study, 59 cases of nasopharyngeal carcinoma were evaluated for expression o

297 rican Joint Committee on Cancer stage II-IVb nasopharyngeal carcinoma were treated with 70-Gy concomi

298 actionated radiotherapy, or including mostly nasopharyngeal carcinomas were excluded.

299 originally identified in cDNA libraries from nasopharyngeal carcinoma, where they are expressed at hi

300 h heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profi